Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.
Identifieur interne : 000395 ( PubMed/Corpus ); précédent : 000394; suivant : 000396Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.
Auteurs : Tülin Morç L ; Brett L. Hurst ; E Bart TarbetSource :
- Vaccine [ 1873-2518 ] ; 2017.
English descriptors
- KwdEn :
- Adjuvants, Immunologic, Aluminum Hydroxide (immunology), Animals, Antibodies, Viral (blood), Calcium Phosphates (immunology), Dose-Response Relationship, Immunologic, Female, Hemagglutination Inhibition Tests, Humans, Immunogenicity, Vaccine, Immunoglobulin G (blood), Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza, Human (prevention & control), Mice, Nanoparticles (chemistry), Neutralization Tests, Off-Label Use, Orthomyxoviridae Infections (prevention & control), Pandemics (prevention & control), Vaccination, Vaccines, Inactivated (administration & dosage), Vaccines, Inactivated (chemistry).
- MESH :
- chemical , administration & dosage : Influenza Vaccines, Vaccines, Inactivated.
- chemical , blood : Antibodies, Viral, Immunoglobulin G.
- chemical , chemistry : Vaccines, Inactivated.
- chemical , immunology : Aluminum Hydroxide, Calcium Phosphates.
- chemical : Adjuvants, Immunologic.
- chemistry : Nanoparticles.
- immunology : Influenza A Virus, H1N1 Subtype.
- prevention & control : Influenza, Human, Orthomyxoviridae Infections, Pandemics.
- Animals, Dose-Response Relationship, Immunologic, Female, Hemagglutination Inhibition Tests, Humans, Immunogenicity, Vaccine, Mice, Neutralization Tests, Off-Label Use, Vaccination.
Abstract
The emergence of pandemic influenza strains, particularly the reemergence of the swine-derived influenza A (H1N1) in 2009, is reaffirmation that influenza viruses are very adaptable and influenza remains as a significant global public health treat. As recommended by the World Health Organization (WHO), the use of adjuvants is an attractive approach to improve vaccine efficacy and allow dose-sparing during an influenza emergency. In this study, we utilized CaPtivate Pharmaceutical's proprietary calcium phosphate nanoparticles (CaPNP) vaccine adjuvant and delivery platform to formulate an inactivated whole virus influenza A/CA/04/2009 (H1N1pdm) vaccine as a potential dose-sparing strategy. We evaluated the relative immunogenicity and the efficacy of the formulation in BALB/c mice following single intramuscularly administration of three different doses (0.3, 1, or 3µg based on HA content) of the vaccine in comparison to non-adjuvanted or alum-adjuvant vaccines. We showed that, addition of CaPNP in vaccine elicited significantly higher hemagglutination inhibition (HAI), virus neutralization (VN), and IgG antibody titers, at all dose levels, relative to the non-adjuvanted vaccine. In addition, the vaccine containing CaPNP provided equal protection with 1/3rd of the antigen dose as compared to the non-adjuvanted or alum-adjuvanted vaccines. Our data provided support to earlier studies indicating that CaPNP is an attractive vaccine adjuvant and delivery system and should play an important role in the development of safe and efficacious dose-sparing vaccines. Our findings also warrant further investigation to validate CaPNP's capacity as an alternative adjuvant to the ones currently licensed for influenza/pandemic influenza vaccination.
DOI: 10.1016/j.vaccine.2017.07.016
PubMed: 28716554
Links to Exploration step
pubmed:28716554Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.</title><author><name sortKey="Morc L, Tulin" sort="Morc L, Tulin" uniqKey="Morc L T" first="Tülin" last="Morç L">Tülin Morç L</name><affiliation><nlm:affiliation>CaPtivate Pharmaceuticals LLC, Doylestown, PA, USA. Electronic address: tmorcol@captivatepharma.com.</nlm:affiliation></affiliation></author><author><name sortKey="Hurst, Brett L" sort="Hurst, Brett L" uniqKey="Hurst B" first="Brett L" last="Hurst">Brett L. Hurst</name><affiliation><nlm:affiliation>Institute for Antiviral Research, Utah State University, Logon, UT, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Tarbet, E Bart" sort="Tarbet, E Bart" uniqKey="Tarbet E" first="E Bart" last="Tarbet">E Bart Tarbet</name><affiliation><nlm:affiliation>Institute for Antiviral Research, Utah State University, Logon, UT, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28716554</idno><idno type="pmid">28716554</idno><idno type="doi">10.1016/j.vaccine.2017.07.016</idno><idno type="wicri:Area/PubMed/Corpus">000395</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000395</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.</title><author><name sortKey="Morc L, Tulin" sort="Morc L, Tulin" uniqKey="Morc L T" first="Tülin" last="Morç L">Tülin Morç L</name><affiliation><nlm:affiliation>CaPtivate Pharmaceuticals LLC, Doylestown, PA, USA. Electronic address: tmorcol@captivatepharma.com.</nlm:affiliation></affiliation></author><author><name sortKey="Hurst, Brett L" sort="Hurst, Brett L" uniqKey="Hurst B" first="Brett L" last="Hurst">Brett L. Hurst</name><affiliation><nlm:affiliation>Institute for Antiviral Research, Utah State University, Logon, UT, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Tarbet, E Bart" sort="Tarbet, E Bart" uniqKey="Tarbet E" first="E Bart" last="Tarbet">E Bart Tarbet</name><affiliation><nlm:affiliation>Institute for Antiviral Research, Utah State University, Logon, UT, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Aluminum Hydroxide (immunology)</term><term>Animals</term><term>Antibodies, Viral (blood)</term><term>Calcium Phosphates (immunology)</term><term>Dose-Response Relationship, Immunologic</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Immunogenicity, Vaccine</term><term>Immunoglobulin G (blood)</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza, Human (prevention & control)</term><term>Mice</term><term>Nanoparticles (chemistry)</term><term>Neutralization Tests</term><term>Off-Label Use</term><term>Orthomyxoviridae Infections (prevention & control)</term><term>Pandemics (prevention & control)</term><term>Vaccination</term><term>Vaccines, Inactivated (administration & dosage)</term><term>Vaccines, Inactivated (chemistry)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin G</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Aluminum Hydroxide</term><term>Calcium Phosphates</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adjuvants, Immunologic</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Nanoparticles</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term><term>Orthomyxoviridae Infections</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Dose-Response Relationship, Immunologic</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Immunogenicity, Vaccine</term><term>Mice</term><term>Neutralization Tests</term><term>Off-Label Use</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The emergence of pandemic influenza strains, particularly the reemergence of the swine-derived influenza A (H1N1) in 2009, is reaffirmation that influenza viruses are very adaptable and influenza remains as a significant global public health treat. As recommended by the World Health Organization (WHO), the use of adjuvants is an attractive approach to improve vaccine efficacy and allow dose-sparing during an influenza emergency. In this study, we utilized CaPtivate Pharmaceutical's proprietary calcium phosphate nanoparticles (CaPNP) vaccine adjuvant and delivery platform to formulate an inactivated whole virus influenza A/CA/04/2009 (H1N1pdm) vaccine as a potential dose-sparing strategy. We evaluated the relative immunogenicity and the efficacy of the formulation in BALB/c mice following single intramuscularly administration of three different doses (0.3, 1, or 3µg based on HA content) of the vaccine in comparison to non-adjuvanted or alum-adjuvant vaccines. We showed that, addition of CaPNP in vaccine elicited significantly higher hemagglutination inhibition (HAI), virus neutralization (VN), and IgG antibody titers, at all dose levels, relative to the non-adjuvanted vaccine. In addition, the vaccine containing CaPNP provided equal protection with 1/3rd of the antigen dose as compared to the non-adjuvanted or alum-adjuvanted vaccines. Our data provided support to earlier studies indicating that CaPNP is an attractive vaccine adjuvant and delivery system and should play an important role in the development of safe and efficacious dose-sparing vaccines. Our findings also warrant further investigation to validate CaPNP's capacity as an alternative adjuvant to the ones currently licensed for influenza/pandemic influenza vaccination.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28716554</PMID><DateCompleted><Year>2018</Year><Month>04</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>35 Pt B</Issue><PubDate><Year>2017</Year><Month>08</Month><Day>16</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.</ArticleTitle><Pagination><MedlinePgn>4569-4577</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(17)30912-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2017.07.016</ELocationID><Abstract><AbstractText>The emergence of pandemic influenza strains, particularly the reemergence of the swine-derived influenza A (H1N1) in 2009, is reaffirmation that influenza viruses are very adaptable and influenza remains as a significant global public health treat. As recommended by the World Health Organization (WHO), the use of adjuvants is an attractive approach to improve vaccine efficacy and allow dose-sparing during an influenza emergency. In this study, we utilized CaPtivate Pharmaceutical's proprietary calcium phosphate nanoparticles (CaPNP) vaccine adjuvant and delivery platform to formulate an inactivated whole virus influenza A/CA/04/2009 (H1N1pdm) vaccine as a potential dose-sparing strategy. We evaluated the relative immunogenicity and the efficacy of the formulation in BALB/c mice following single intramuscularly administration of three different doses (0.3, 1, or 3µg based on HA content) of the vaccine in comparison to non-adjuvanted or alum-adjuvant vaccines. We showed that, addition of CaPNP in vaccine elicited significantly higher hemagglutination inhibition (HAI), virus neutralization (VN), and IgG antibody titers, at all dose levels, relative to the non-adjuvanted vaccine. In addition, the vaccine containing CaPNP provided equal protection with 1/3rd of the antigen dose as compared to the non-adjuvanted or alum-adjuvanted vaccines. Our data provided support to earlier studies indicating that CaPNP is an attractive vaccine adjuvant and delivery system and should play an important role in the development of safe and efficacious dose-sparing vaccines. Our findings also warrant further investigation to validate CaPNP's capacity as an alternative adjuvant to the ones currently licensed for influenza/pandemic influenza vaccination.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morçӧl</LastName><ForeName>Tülin</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>CaPtivate Pharmaceuticals LLC, Doylestown, PA, USA. Electronic address: tmorcol@captivatepharma.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurst</LastName><ForeName>Brett L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Institute for Antiviral Research, Utah State University, Logon, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarbet</LastName><ForeName>E Bart</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Institute for Antiviral Research, Utah State University, Logon, UT, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HHSN272201000039C</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN272201000039I</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002130">Calcium Phosphates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>5QB0T2IUN0</RegistryNumber><NameOfSubstance UI="D000536">Aluminum Hydroxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>97Z1WI3NDX</RegistryNumber><NameOfSubstance UI="C020243">calcium phosphate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="Y">Adjuvants, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000536" MajorTopicYN="N">Aluminum Hydroxide</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002130" MajorTopicYN="N">Calcium Phosphates</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004306" MajorTopicYN="N">Dose-Response Relationship, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056687" MajorTopicYN="N">Off-Label Use</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Adjuvant</Keyword><Keyword MajorTopicYN="Y">Calcium phosphate nanoparticle</Keyword><Keyword MajorTopicYN="Y">Dose-sparing</Keyword><Keyword MajorTopicYN="Y">Influenza</Keyword><Keyword MajorTopicYN="Y">Vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>12</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>06</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>07</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28716554</ArticleId><ArticleId IdType="pii">S0264-410X(17)30912-X</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2017.07.016</ArticleId><ArticleId IdType="pmc">PMC5562532</ArticleId><ArticleId IdType="mid">NIHMS891442</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Infect Dis. 1999 Sep;180(3):579-85</Citation><ArticleIdList><ArticleId IdType="pubmed">10438342</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Diagn Lab Immunol. 2000 Nov;7(6):899-903</Citation><ArticleIdList><ArticleId IdType="pubmed">11063495</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Diagn Lab Immunol. 2002 Sep;9(5):1021-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12204953</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Immunol. 2005 Jul;62(1):36-44</Citation><ArticleIdList><ArticleId IdType="pubmed">16092921</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2005 Oct 6;437(7060):889-93</Citation><ArticleIdList><ArticleId IdType="pubmed">16208372</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Vaccine Immunol. 2006 Sep;13(9):981-90</Citation><ArticleIdList><ArticleId IdType="pubmed">16960108</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2006 Nov 1;194 Suppl 2:S111-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17163383</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2008 May 29;453(7195):615-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18418375</ArticleId></ArticleIdList></Reference><Reference><Citation>Microbes Infect. 2009 Jul-Aug;11(8-9):725-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19442755</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 May 22;58(19):521-4</Citation><ArticleIdList><ArticleId IdType="pubmed">19478718</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Microbiol. 2009 Oct 20;139(1-2):58-66</Citation><ArticleIdList><ArticleId IdType="pubmed">19505774</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2009 Jun 18;459(7249):931-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19525932</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Dec 17;361(25):2424-35</Citation><ArticleIdList><ArticleId IdType="pubmed">19745215</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Dec 17;361(25):2414-23</Citation><ArticleIdList><ArticleId IdType="pubmed">19846844</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2010 Jan 2;375(9708):41-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20018365</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2010 Jan 6;303(1):37-46</Citation><ArticleIdList><ArticleId IdType="pubmed">20026597</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Microbiol Immunol. 2010 May;199(2):117-21</Citation><ArticleIdList><ArticleId IdType="pubmed">20162304</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2010 May;9(5):497-502</Citation><ArticleIdList><ArticleId IdType="pubmed">20450324</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2010 May 06;15(18):null</Citation><ArticleIdList><ArticleId IdType="pubmed">20460094</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2010 Sep;84(17):8607-16</Citation><ArticleIdList><ArticleId IdType="pubmed">20592084</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Aug 16;28(36):5837-44</Citation><ArticleIdList><ArticleId IdType="pubmed">20600478</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2010 Sep 15;51(6):668-77</Citation><ArticleIdList><ArticleId IdType="pubmed">20687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2010 Dec;9(12):1385-98</Citation><ArticleIdList><ArticleId IdType="pubmed">21105775</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Vaccine Immunol. 2011 Mar;18(3):520-2</Citation><ArticleIdList><ArticleId IdType="pubmed">21228145</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2011 Jan 1;52 Suppl 1:S75-82</Citation><ArticleIdList><ArticleId IdType="pubmed">21342903</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2011 May;127(5):e1161-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21464195</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011;6(6):e20928</Citation><ArticleIdList><ArticleId IdType="pubmed">21687743</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 2012 Jul;31(7):e92-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22481427</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2012 Sep;12(9):687-95</Citation><ArticleIdList><ArticleId IdType="pubmed">22738893</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2013 Mar 15;31(12):1646-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22749796</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunotoxicol. 2014 Jan-Mar;11(1):44-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23506358</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 May 16;368(20):1888-97</Citation><ArticleIdList><ArticleId IdType="pubmed">23577628</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2013 Oct;19(10):1305-12</Citation><ArticleIdList><ArticleId IdType="pubmed">24056771</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanomedicine. 2014 Apr;10(3):571-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24275478</ArticleId></ArticleIdList></Reference><Reference><Citation>Avian Dis. 2014 Mar;58(1):46-52</Citation><ArticleIdList><ArticleId IdType="pubmed">24758112</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccines (Basel). 2014 Oct 13;2(4):707-34</Citation><ArticleIdList><ArticleId IdType="pubmed">26344888</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2016 Oct 26;34(45):5410-5413</Citation><ArticleIdList><ArticleId IdType="pubmed">27531411</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin Immunother. 2017 Nov 2;13(11):2612-2625</Citation><ArticleIdList><ArticleId IdType="pubmed">28933657</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Biol Stand. 1986;65:131-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3549396</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Immunol (Paris). 1983 Nov-Dec;134D(3):385-98</Citation><ArticleIdList><ArticleId IdType="pubmed">6675525</ArticleId></ArticleIdList></Reference><Reference><Citation>Microbiol Immunol. 1994;38(7):543-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7968687</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 1997 Jun;15(9):1039-44</Citation><ArticleIdList><ArticleId IdType="pubmed">9261954</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1997 Oct 9;389(6651):554</Citation><ArticleIdList><ArticleId IdType="pubmed">9335492</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000395 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000395 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28716554
|texte= Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28716554" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |